Dexcom (DXCM) Current Deferred Revenue (2010 - 2025)

Dexcom (DXCM) has 16 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q3 2025.

• Current Deferred Revenue for Q3 2025 came in at $2.9 million, down 79.14% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.9 million (down 79.14% YoY), and the FY2024 annual result was $8.0 million, down 56.52% from the prior year.
• Current Deferred Revenue eased to $2.9 million in Q3 2025 per DXCM's latest filing, from $6.1 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $18.4 million in Q4 2023 and troughed at $1.8 million in Q2 2021.
• A 5-year average of $7.5 million and a median of $7.8 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue soared 380.95% in 2022, then sank 79.14% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $2.1 million in 2021, then soared by 380.95% to $10.1 million in 2022, then soared by 82.18% to $18.4 million in 2023, then tumbled by 56.52% to $8.0 million in 2024, then slumped by 63.75% to $2.9 million in 2025.
• Business Quant data shows DXCM's Current Deferred Revenue at $2.9 million in Q3 2025, $6.1 million in Q2 2025, and $7.8 million in Q1 2025.